SLC5A2 and autosomal dominant polycystic kidney disease: The EMPA-PKD trial is a randomized, double-blind, placebo-controlled clinical study designed to evaluate the safety and potential efficacy of empagliflozin, an SGLT2 inhibitor, in patients with rapidly progressive ADPKD [122].